Radiation

Voting Rights and Shares Capital of the Company

Retrieved on: 
Thursday, December 8, 2022

PARIS, Dec. 08, 2022 (GLOBE NEWSWIRE) --

Key Points: 
  • (1) The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings.
  • In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
  • (2)The total number of exercisable at a Shareholders’ Meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company.
  • Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity.

Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment

Retrieved on: 
Wednesday, December 7, 2022

These initial study results are being presented in a poster session at the annual San Antonio Breast Cancer Symposium (SABCS), December 6 - 10, 2022.

Key Points: 
  • These initial study results are being presented in a poster session at the annual San Antonio Breast Cancer Symposium (SABCS), December 6 - 10, 2022.
  • “These are the first data to show the beneficial effect of a single dose of trilaciclib, one week after administration, on the tumor microenvironment.
  • Results one week after a single dose of trilaciclib show a trend toward an increased ratio of CD8+ T-cells to Tregs within the tumor microenvironment, indicating trilaciclib may favorably modulate the composition of immune cells to support antitumor immune responses.
  • Patients then received a single dose of monotherapy (240 mg/m2) trilaciclib, followed by a tumor biopsy approximately one week later to assess the ability of a single dose of trilaciclib monotherapy to favorably alter the tumor microenvironment.

Branded Legacy, Inc. Adds Subsidiary Bringing Additional $750,000 in Revenues

Retrieved on: 
Wednesday, December 7, 2022

Brandon Spikes, chairman of Branded Legacy, Inc., stated, "We are excited to be working with this Florida based company.

Key Points: 
  • Brandon Spikes, chairman of Branded Legacy, Inc., stated, "We are excited to be working with this Florida based company.
  • ReelSkinz brings with them just under a million dollars in revenues a year which adds much value for our loyal shareholders.
  • ReelSkinz is more than just a lifestyle brand; it is a company that combines practicality, protection, and fashion into the ultimate ocean and outdoor apparel.
  • Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated.

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Retrieved on: 
Wednesday, December 7, 2022

WOBURN, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical. The IGNYTE clinical trial is evaluating RP1 (vusolimogene oderparepvec) in combination with nivolumab, with the anti-PD1 failed melanoma cohort being conducted with registrational intent. The Company also provided new data from the ongoing Phase 1 clinical trials evaluating RP2 and RP3, as well as a detailed overview of its RP2/3 Phase 2 development plans. A virtual investor event will be held today at 8:00 a.m. ET to discuss the new data. The data from this update can be found in the presentation for today’s investor event, linked here.

Key Points: 
  • The IGNYTE clinical trial is evaluating RP1 (vusolimogene oderparepvec) in combination with nivolumab, with the anti-PD1 failed melanoma cohort being conducted with registrational intent.
  • The Company is today presenting new data from the first 75 patients from the 125 patient anti-PD1 failed melanoma cohort, which has registrational intent.
  • The IGNYTE clinical trial is being conducted under a collaboration and supply agreement with Bristol-Myers Squibb, with the anti-PD1 failed melanoma cohort expected to complete enrollment by around the end of this year.
  • This cohort was initiated after completing enrollment in a prior Phase 2 cohort in the same clinical trial of approximately 30 patients with melanoma.

Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)

Retrieved on: 
Monday, December 5, 2022

ImmuneOncia is a biotechnology company specializing in immuno-oncology drug development, jointly established by Yuhan Corporation of Korea and Sorrento .

Key Points: 
  • ImmuneOncia is a biotechnology company specializing in immuno-oncology drug development, jointly established by Yuhan Corporation of Korea and Sorrento .
  • The Phase II NK/T-cell lymphoma study was selected for an oral presentation at the Asian Congress of the European Society for Medical Oncology (ESMO Asia 2022) in Singapore on December 4th, 2022.
  • Due to the absence of standard-of-care treatment for relapsed/refractory cases, NK/T lymphoma represents a high unmet medical need and significant market opportunity.
  • RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients.

Humanetics Corporation Presents at the MedInvest Oncology Investor Conference

Retrieved on: 
Friday, December 16, 2022

Humanetics Corporation, a clinical-stage pharmaceutical company focused on novel products to improve outcomes for patients with cancer, presented at the MedInvest Oncology Investor Conference in New York City on December 15, 2022.

Key Points: 
  • Humanetics Corporation, a clinical-stage pharmaceutical company focused on novel products to improve outcomes for patients with cancer, presented at the MedInvest Oncology Investor Conference in New York City on December 15, 2022.
  • At the conference, Ronald Zenk, President and Chief Executive Officer at Humanetics, delivered a corporate overview and details on the companys lead drug candidate, BIO 300.
  • BIO 300 is a new class of drug focused on improving outcomes in cancer patients who receive first-line radiotherapy with or without concurrent chemotherapy.
  • These patients suffer from myriad unintended side effects, which can reduce the efficacy of treatment and/or result in serious toxicities.

OPN Healthcare Partners with KAID Health to Leverage Natural Language Processing Technology for Value-Based Oncology Care

Retrieved on: 
Thursday, December 15, 2022

KAID Health , an AI-powered health care data analysis and provider engagement platform, has partnered with OPN Healthcare , a U.S. network of community oncology providers to improve oncology care delivery.

Key Points: 
  • KAID Health , an AI-powered health care data analysis and provider engagement platform, has partnered with OPN Healthcare , a U.S. network of community oncology providers to improve oncology care delivery.
  • NLITE addresses key technological issues that to-date have hindered the widespread adoption of natural language processing (NLP) for prior authorization.
  • KAID Healths NLITE technology helps OPN Healthcare, and its oncology provider partners, by automatically extracting patient data from the medical record.
  • KAID Health makes care delivery more efficient, effective, and profitable for providers and their payers and Accountable Care Organization partners.

Global Anti-Drone Systems Market Report 2022-2028: Size, Segments, Outlook, and Revenue Forecasts - Automatic Dependent Surveillance-Broadcast (ADS-B) is Driving Demand - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 15, 2022

Anti-Drone Systems also known as Counter-Drone Systems detect and/or intercept unauthorized drones and unmanned aerial vehicles (UAVs).

Key Points: 
  • Anti-Drone Systems also known as Counter-Drone Systems detect and/or intercept unauthorized drones and unmanned aerial vehicles (UAVs).
  • The advancement of remote sensing and surveillance technologies, such as automatic dependent surveillance-broadcast (ADS-B) is driving the demand for Anti-Drone.
  • By Technology: The laser system segment held the largest market share of the global Anti-Drone systems market in 2021.
  • The Global Anti-Drone Systems Market is covered from 2017-2028 in this report, including a forecast for 2022-2028
    What is the Future Growth Rate of the Global Anti-Drones Systems Market?

World Healthcare Industry Almanac 2023: Market Research, Statistics, Trends and Leading Companies - ResearchAndMarkets.com

Retrieved on: 
Monday, December 12, 2022

How is the industry being shaped by new technologies?

Key Points: 
  • How is the industry being shaped by new technologies?
  • How is demand growing in emerging markets and mature economies?
  • What is the size of the market now and in the future?
  • What are the financial results of the leading companies?

QT Imaging and GigCapital5 Announce Signing of Business Combination Agreement to Bring Breast and Full Body Imaging Solutions to the Public Markets

Retrieved on: 
Monday, December 12, 2022

QT Imaging exists to provide an improved imaging modality to address critical deficiencies in the current breast imaging paradigm.

Key Points: 
  • QT Imaging exists to provide an improved imaging modality to address critical deficiencies in the current breast imaging paradigm.
  • QT Imagings core mission is to provide safe, highly accurate and inexpensive imaging systems to women and children, said John Klock, MD, Founder and CEO of QT Imaging.
  • The QT Imaging Breast Scanner is indicated for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patients breast.
  • This communication is being made in respect of the proposed business combination involving QT Imaging, GigCapital5 and GigCapital5s wholly-owned subsidiary, QTI Merger Sub, Inc.